Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This May Allow Longer Survival in People with AML

Biol Blood Marrow Transplant; ePub 2017 Jul 25; Imus, et al

Publish date:: September 6, 2017

Second allogenic (allo) bone or marrow transplants (BMTs) appear to safely provide patients with acute myeloid leukemia (AML) the opportunity for long-term survival, according to a study involving 40 individuals. This is particularly true for those whose allograft contains a new mismatched haplotype.

Participants received a second BMT due to relapse between 2005 and 2015. Investigators looked at outcomes in patients who did and did not receive an allograft with a new mismatched haplotype. Among the results:

Median overall survival was 928 days, and the 4-year overall survival rate was 40%.
Median event-free survival was 500 days, and the 4-year overall survival rate was 36%.
2-year nonrelapsed mortality rate was 27%.
Patients undergoing a second allograft who did not have a new mismatched haplotype survived a median of 552 days; event-free survival was a median of 401 days.
Those whose allograft contained a new mismatched haplotype experienced longer overall and event-free survival; these endpoints were not reached in this group.

Citation:

Imus P, Blackford A, Bettinotti M, et al. Major histocompatibility mismatch and donor choice for second allogeneic bone marrow transplantation. [Published online ahead of print July 25, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.07.014.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in AML

Azacitidine in Lower-Risk MDS Shows Promise, Oncologist; ePub 2017 Nov 8; Komrokji, et al

Clostridium Difficile Infection in People with MDS, World J Clin Oncol; 2017 Oct 10; Shaht, et al

Survival in Azacitidine-Treated Patients Assessed, Leuk Res; 2017 Oct 27; Sébert, Komrokji et al

Use This to Evaluate MRD Prior to Allo-SCT, Leuk Res; 2017 Dec; Candoni, De Marchi, et al

Detecting Minimal Residual Disease in AML, Curr Hematol Malig Rep; ePub 2017 Nov 2; Zhou, et al